{"id":3301,"date":"2026-09-18T09:00:00","date_gmt":"2026-09-18T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3301"},"modified":"2026-09-19T14:11:30","modified_gmt":"2026-09-19T18:11:30","slug":"bristol-myers-ends-clinical-development-of-orm-6151","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3301","title":{"rendered":"Bristol Myers Ends Clinical Development of ORM-6151"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Orum Therapeutics \/ Bristol Myers Squibb<\/p>\n

Event Type<\/strong><\/p>\n

Program Discontinuation<\/p>\n

Modality<\/strong><\/p>\n

Degrader-Antibody Conjugate<\/p>\n

Asset<\/strong><\/p>\n

ORM-6151 (BMS-986497)<\/p>\n

Target<\/strong><\/p>\n

CD33-Directed Delivery of a GSPT1 Molecular-Glue Degrader<\/p>\n

Disease Area<\/strong><\/p>\n

Acute Myeloid Leukemia and Myelodysplastic Syndrome<\/p>\n

Summary<\/h4>\n

Bristol Myers Squibb discontinued the Phase I program for ORM-6151, also known as BMS-986497, after reviewing clinical data in AML and MDS. The CD33-targeted degrader-antibody conjugate carried a GSPT1 molecular-glue payload and was the only clinical-stage program in this modality. Orum retains the $100 million upfront payment from the 2023 asset sale but loses eligibility for up to $80 million in remaining development milestones. The decision is negative for the asset and a material setback for clinical validation of degrader-antibody conjugates as a class.<\/p>\n

Orum filed the material disclosure on September 17, 2026, with broad biotechnology-media coverage following on September 18. BMS had been evaluating the agent alone and in combination with azacitidine and venetoclax in relapsed or refractory AML and MDS. The filing states that development was discontinued after clinical-data review; BMS and Orum did not disclose response rate, exposure, target-degradation, cytokine, cytopenia, hepatotoxicity, infection, or mortality details. Because the 2023 transaction was a full asset sale, ORM-6151 does not revert to Orum. Orum said it will focus on its internal degrader-antibody-conjugate pipeline.<\/p>\n

Deep Analysis<\/h4>\n

The most concerning interpretation is that early human data failed on safety, exposure, pharmacodynamics, or therapeutic index, directly challenging the premise that an antibody can deliver a potent degrader payload with enough selectivity in myeloid disease. A less damaging interpretation is that BMS made a portfolio-prioritization decision before a fully optimized dose or combination regimen had been tested. The disclosed phrase “after reviewing clinical data” supports a program-specific evidence problem but does not identify its nature. CD33 is broadly expressed on normal myeloid cells as well as malignant blasts, so marrow toxicity and on-target, off-tumor effects are intrinsic risks for this class of conjugate.<\/p>\n

The thesis for degrader-antibody conjugates can only recover through transparent disclosure of the actual clinical data, improved linker or payload design in next-generation candidates, and eventual success of a successor program such as Orum’s ORM-1153. It would be falsified at the platform level only if similar degrader-antibody conjugates repeatedly fail to achieve target degradation at a tolerable exposure across independent programs.<\/p>\n

Company and Product Background<\/h4>\n

Degrader-antibody conjugates replace a conventional cytotoxic antibody-drug-conjugate payload with a targeted-protein-degradation payload, aiming to combine antibody-mediated tumor selectivity with the catalytic, sub-stoichiometric activity of small-molecule degraders. ORM-6151 used a CD33-targeting antibody to deliver a GSPT1 molecular-glue degrader to myeloid malignancies. Orum Therapeutics originated the program and sold it to Bristol Myers Squibb in 2023. AML and MDS create a difficult delivery and therapeutic-index setting because target-positive malignant and normal myeloid cells coexist within the bone marrow.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Program status: Phase I discontinued by Bristol Myers Squibb after clinical-data review.<\/li>\n
  • Financial consequence for Orum: retains the $100 million 2023 upfront but forfeits eligibility for up to $80 million in remaining milestones; asset does not revert since the transaction was a full sale.<\/li>\n
  • Evidence gap: no patient-level response, exposure, target-degradation, or safety data disclosed publicly.<\/li>\n
  • Platform implication: removal of the only clinical-stage degrader-antibody conjugate increases uncertainty for the entire modality pending new data.<\/li>\n
  • Upgrade path: transparent disclosure of the underlying clinical data, and eventual clinical success of a next-generation degrader-antibody conjugate with improved design.<\/li>\n
  • Falsifier at platform level: repeated failure of independently developed degrader-antibody conjugates to achieve target degradation at tolerable exposure.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a high-importance negative technology signal, but causation should not be invented from a single disclosed sentence. The discontinuation weakens clinical validation of degrader-antibody conjugates as a modality and raises the evidentiary bar for successor programs. It does not prove that all degrader-antibody-conjugate architectures are nonviable; it proves that the first disclosed clinical-stage program failed to justify continued development on the data BMS reviewed.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal importance is high because this was the only clinical-stage program validating the degrader-antibody-conjugate modality, and its discontinuation removes the field’s primary human proof point. Direction is negative given the outright discontinuation. Confidence in the underlying facts is high, since the discontinuation and financial consequences are documented in Orum’s material filing, while confidence in interpretation is moderate because no patient-level clinical or safety data have been disclosed to explain the decision.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Bristol Myers Squibb discontinued the Phase I program for ORM-6151, also known as BMS-986497, after reviewing clinical data in AML and MDS. The CD33-targeted degrader-antibody conjugate carried a GSPT1 molecular-glue payload and was the…<\/p>\n","protected":false},"author":1,"featured_media":3308,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[76,101,813],"class_list":["post-3301","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-acute-myeloid-leukemia","tag-bristol-myers-squibb","tag-orum-therapeutics"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3301"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3301\/revisions"}],"predecessor-version":[{"id":3312,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3301\/revisions\/3312"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3308"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}